Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 305

1.

Access to care of patients with chronic hepatitis C virus infection in a university hospital: Is opioid dependence a limiting condition?

Perut V, Labalette C, Sogni P, Ferrand I, Salmon-Céron D, Vidal-Trecan G.

Drug Alcohol Depend. 2009 Sep 1;104(1-2):78-83. doi: 10.1016/j.drugalcdep.2009.04.002. Epub 2009 May 21.

PMID:
19464124
2.

Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment.

Watson B, Conigrave KM, Wallace C, Whitfield JB, Wurst F, Haber PS.

Drug Alcohol Rev. 2007 May;26(3):231-9.

PMID:
17454012
3.

The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.

Loguercio C, Federico A, Masarone M, Torella R, Blanco Cdel V, Persico M.

Am J Gastroenterol. 2008 Dec;103(12):3159-66. doi: 10.1111/j.1572-0241.2008.02159.x. Epub 2008 Sep 11.

PMID:
18786125
4.

[Chronic hepatitis C virus infection and associated liver disease among the inmates of a Spanish prison].

Murcia J, Portilla J, Bedia M, Palazón JM, Sánchez-Payá J, Saiz de la Hoya P, Payá A, Boix V, Merino E, Reus S.

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):206-12. doi: 10.1016/j.eimc.2008.07.003. Epub 2009 Feb 25. Spanish.

PMID:
19246126
5.
6.

Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002.

Schiavini M, Angeli E, Mainini A, Zerbi P, Duca PG, Gubertini G, Vago L, Fociani P, Giorgi R, Cargnel A.

HIV Med. 2006 Jul;7(5):331-7.

7.

Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis.

d'Arminio Monforte A, Cozzi-Lepri A, Castagna A, Antinori A, De Luca A, Mussini C, Caputo SL, Arlotti M, Magnani G, Pellizzer G, Maggiolo F, Puoti M; Icona Foundation Study Group.

Clin Infect Dis. 2009 Aug 15;49(4):612-22. doi: 10.1086/603557.

8.

Hepatitis C among predialysis patients: prevalence and characteristics in a large cohort of patients.

Lemos LB, Perez RM, Lemos MM, Draibe SA, Silva IS, Silva AE, Ferraz ML.

Nephron Clin Pract. 2008;108(2):c135-40. doi: 10.1159/000114452. Epub 2008 Jan 30.

PMID:
18230916
9.

The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997-2006.

Gidding HF, Topp L, Middleton M, Robinson K, Hellard M, McCaughan G, Maher L, Kaldor JM, Dore GJ, Law MG.

J Gastroenterol Hepatol. 2009 Oct;24(10):1648-54.

PMID:
19798783
10.

Factors associated with severity of hepatic fibrosis in people with chronic hepatitis C infection.

Danta M, Dore GJ, Hennessy L, Li Y, Vickers CR, Harley H, Ngu M, Reed W, Desmond PV, Sievert W, Farrell GC, Kaldor JM, Batey RG.

Med J Aust. 2002 Sep 2;177(5):240-5.

PMID:
12197817
11.

Management of chronic hepatitis C in French departments of internal medicine and infectious diseases.

Cacoub P, Goderel I, Morlat P, Sene D, Myers RP, Alric L, Loustaud-Ratti V, Melin P, Limal N, Ouzan D, Perronne C, Carrat F; GERMIVIC Group.

Epidemiol Infect. 2005 Apr;133(2):305-14.

12.

Risks factors of liver fibrosis in a cohort of intravenous drug users coinfected with HIV and HCV in the HAART era: the role of mixed steatosis.

Lanternier F, Roulot D, Bentata M, Pol S, Viard JP, Gordien E, Jeantils V, Ziol M, Lortholary O.

Gastroenterol Clin Biol. 2007 Oct;31(10):822-7.

13.

Factors associated with the development of cirrhosis in patients with HCV chronic infection.

Dinis-Ribeiro M, Ramalho F, Glória H, Marinho R, Raimundo M, Serejo F, Velosa J, Carneiro-de-Moura M.

Hepatogastroenterology. 2005 Jan-Feb;52(61):176-9.

PMID:
15783023
14.

Outcomes of a Hepatitis C screening program at a large urban VA medical center.

Groom H, Dieperink E, Nelson DB, Garrard J, Johnson JR, Ewing SL, Stockley H, Durfee J, Jonk Y, Willenbring ML, Ho SB.

J Clin Gastroenterol. 2008 Jan;42(1):97-106.

PMID:
18097298
15.

Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection.

Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ.

Liver Int. 2009 Aug;29(7):1051-5. doi: 10.1111/j.1478-3231.2008.01958.x.

PMID:
19580634
16.

Antiviral treatment for hepatitis C virus infection: effectiveness at general population level in a highly endemic area.

Mariano A, Caserta C, Pendino GM, Vacalebre C, Surace P, Fiorillo MT, Polito I, Surace M, Alicante S, Amante A, Foti G, Marra M, Gutamo G, Amato F, Messineo A, Mele A.

Dig Liver Dis. 2009 Jul;41(7):509-15. doi: 10.1016/j.dld.2008.11.011. Epub 2009 Feb 3.

PMID:
19196557
17.

The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype.

Aghemo A, Rumi MG, Monico S, Prati GM, D'Ambrosio R, Donato MF, Colombo M.

Antivir Ther. 2009;14(4):577-84.

PMID:
19578243
18.

Opioid use disorder in the United States: insurance status and treatment access.

Becker WC, Fiellin DA, Merrill JO, Schulman B, Finkelstein R, Olsen Y, Busch SH.

Drug Alcohol Depend. 2008 Apr 1;94(1-3):207-13. doi: 10.1016/j.drugalcdep.2007.11.018. Epub 2008 Jan 25.

PMID:
18222051
19.

Virological response of Tunisians patients treated by peginterferon plus ribavirin for chronic hepatitis C: a preliminary study.

Belhadj N, Houissa F, Elloumi H, Ouakaa A, Gargouri D, Romani M, Kilani A, Kochlef A, Kharrat J, Ghorbel A.

Tunis Med. 2008 Apr;86(4):341-5.

PMID:
19476135
20.

Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis.

Aguilera V, Berenguer M, Rubín A, San-Juan F, Rayón JM, Prieto M, Mir J.

Liver Transpl. 2009 Jan;15(1):79-87. doi: 10.1002/lt.21626.

Items per page

Supplemental Content

Write to the Help Desk